Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial–mesenchymal transition suppression
The Korean Journal of Physiology & Pharmacology · 01.07.2026 · 30 (4) · 361-375
DOI: 10.4196/kjpp.25.369 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Korean Journal of Physiology & Pharmacology, erschienen am 01.07.2026. Verfasst von Yanling Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54907, Korea. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Biomedical Research Institute, Jeonbuk National University Hospital.
Abstract (Originalsprache)
Bone morphogenetic protein-2 (BMP-2) regulates cell differentiation and proliferation. However, its role in colorectal cancer (CRC) remains debatable owing to potential oncogenic effects. Here, we investigated the role of BMP-2 in modulating CRC progression, particularly in regulating the Hippo signaling pathway. Exposure to recombinant human BMP-2 (rhBMP-2) resulted in a concentration-dependent decrease in CRC cell proliferation, leading to G1 cell cycle arrest. This effect was associated with the increased expression of p53, p21, and Smad4, while the levels of cyclin D1, cyclin-dependent kinase 4 (CDK4), and CDK6 decreased. Additionally, rhBMP-2 promoted apoptosis by decreasing poly (ADP-ribose) polymerase and caspase-9 expression while increasing their cleaved forms. It also activated the Hippo signaling cascade, enhancing the expression of mammalian sterile 20-like kinase 1/2, Mps One Binder 1 (MOB1), phosphorylated MOB1, and Salvador homolog, along with elevated levels of phosphorylated yes-associated protein (YAP), while concurrently suppressing total YAP expression. This resulted in cytoplasmic sequestration and subsequent degradation of YAP, thereby attenuating the transcription of YAP-responsive genes such as Connective Tissue Growth Factor. Silencing of Ras association domain family member 1 restored the rhBMP-2-induced decrease in cell viability, whereas silencing YAP further reduced the viability of CRC cell lines. Administering rhBMP-2 significantly suppressed tumor expansion in a mouse model of CRC, further supporting its potential as an antitumor agent. Collectively, these results indicate that rhBMP-2 mitigates CRC progression by activating the Hippo signaling pathway and suppressing YAP-mediated oncogenic processes, thereby highlighting its potential as a therapeutic agent that warrants further clinical evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju 54907, Korea.
- Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju 54907, Korea.
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea.
- Department of Pediatrics, Jeonbuk National University Medical School, Jeonju 54907, Korea.
- Biosafety Research Institute and Laboratory of Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Korea.
- Department of Orthopedic Surgery, Jeonju Hospital, Jeonju 54907, Korea.
ORCID-Profile: Kwang-Bok Lee, Soo Mi Kim
Förderung
- Biomedical Research Institute, Jeonbuk National University Hospital
Zitieren
APA
Wu, Y., Lee, N. R., Liu, Y. C., Kim, M. S., Hwang, S., Kim, B., Lee, K. B., & Kim, S. M. (2026). Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial–mesenchymal transition suppression. The Korean Journal of Physiology & Pharmacology, 30(4), 361-375. https://doi.org/10.4196/kjpp.25.369
Vancouver
Wu Y, Lee NR, Liu YC, Kim MS, Hwang S, Kim B, et al. Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial–mesenchymal transition suppression. The Korean Journal of Physiology & Pharmacology. 2026;30(4):361-375. doi:10.4196/kjpp.25.369
BibTeX
@article{Wu2026,
author = {Wu, Yanling and Lee, Na-Ri and Liu, Yu Chuan and Kim, Min Sun and Hwang, Seongwon and Kim, Bumseok and Lee, Kwang-Bok and Kim, Soo Mi},
title = {Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial–mesenchymal transition suppression},
journal = {The Korean Journal of Physiology & Pharmacology},
year = {2026},
volume = {30},
number = {4},
pages = {361--375},
doi = {10.4196/kjpp.25.369}
}
EUVIMED